Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Ebersberg – page 48

1 343 clinical trials in Ebersberg, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Ebersberg at a glance
1 343
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 343 trials in Ebersberg

Open in trial search

Non-small cell lung cancer+1

Not yet recruiting

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Tislelizumab with drug combination in patients with PD-L1‑high metastatic non‑small cell lung cancer and high tumor burden

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AIO-Studien gGmbH

Adenocarcinoma pancreas

Not yet recruiting

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Non-small cell lung cancer

Not yet recruiting

Pembrolizumab alone versus pembrolizumab with chemotherapy drug combination in women with advanced non‑small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

Plasma cell myeloma

Not yet recruiting

A Phase III Study of AZD0120 versus melphalan hydrochloride with lenalidomide maintenance in transplant‑eligible adults with newly diagnosed multiple myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD0120
  • Sponsor:AstraZeneca AB

Safety and Efficacy of Extended‑Release Tacrolimus (VI‑0106) in Adults with Pulmonary Arterial Hypertension and Functional Limitations

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Vivus B.V.

Acute myeloid leukaemia

Not yet recruiting

A Phase 1/2 study of CHM-029 alone and in combination drug regimen in adults with newly diagnosed, relapsed or refractory Acute Myeloid Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Charm Therapeutics Limited

Metastatic malignant melanoma+2

Not yet recruiting

Methoxsalen (ECP) versus drug combination for steroid‑refractory immune‑related colitis or hepatitis in metastatic melanoma on checkpoint therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Therakos Europe Limited

Retinal dystrophy

Not yet recruiting

A Study of ATSN-201 Gene Therapy for Patients with X-linked Retinoschisis (RS1-associated) to Assess Safety and Visual Function

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ziloretgene parvec
  • Sponsor:Atsena Therapeutics Inc.

Study of dapirolizumab pegol placental transfer to infants in pregnant women with active systemic lupus erythematosus (drug combination)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Benzocaine
  • Sponsor:UCB Biopharma

Ischaemic stroke

Not yet recruiting

Enhanced dual antiplatelet therapy with clopidogrel and acetylsalicylic acid for secondary prevention in patients with mild ischemic stroke

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Technische Universitat Dresden

Endometrial cancer

Not yet recruiting

Study of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GSK5733584
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Ebersberg

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on triple-negative breast cancer treatment, evaluating the effectiveness of combining immunotherapy with conventional chemotherapy approaches.

  • Neoadjuvant Chemotherapy Studies
  • Immunotherapy Integration
  • Event-free Survival Assessment

Research aims to enhance treatment outcomes through targeted therapeutic combinations.

02 Genetic-Based Treatment

Studies examining treatment efficacy in patients with BRCA mutations, specifically targeting high-risk HER2-negative breast cancer cases.

  • Adjuvant Therapy Development
  • Invasive Disease Management
  • Targeted Treatment Approaches

Focused on improving survival rates through genetically-informed treatment strategies.

03 Hormone Receptor Research

Investigation of advanced treatment protocols for HR+/HER2- early breast cancer, combining endocrine therapy with innovative therapeutic agents.

  • Long-term Endocrine Therapy
  • Combination Treatment Protocols
  • Disease-free Survival Studies

Evaluating enhanced treatment strategies for hormone-responsive breast cancers.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.